Merck comp data: Finance Manager, NJ, 2026

finance_faye · 4 replies

sharing actual numbers since these threads help me when i'm doing research. just declined a Merck offer to take something in biotech, so numbers are fresh.

Role: Finance Manager, FP&A Location: Rahway NJ (hybrid, 3 days onsite) Level: roughly equivalent to a VP/senior manager depending on your background

Offer: Base: $142,000 Target annual bonus: 15% of base ($21,300 at target) RSUs: $40,000 over 4 years, cliff at year 1 401k match: 4% dollar-for-dollar + up to 2% additional company contribution based on salary grade Benefits were strong, healthcare was notably good for pharma, which matters

Total comp at target was around $177k not counting benefits value. They would not move on bonus target (tied to grade level). They did move on base from $135k to $142k when i pushed with a competing offer. No flexibility on RSU amount at this level.

For reference, my background is 6 years corp finance, MBA from a state school, no pharma specific experience. They weighed the industry gap during leveling, which is why i think i landed mid-band rather than high.

4 replies

contractor_kai

that 6% match structure (4+2) is better than most of the F500 i've tracked. people undercount that. on a $142k base you're looking at $8,520/yr in match at max. over 10 years that adds up more than the RSU grant at this level.

numbers_only

thanks for the data. comparable pharma FP&A roles in NJ i've seen range $130-155k base at manager level. $142k after negotiation sounds like a fair landing spot for non-pharma background. the hybrid 3-day is also a constraint for some people. did they say whether that was firm?

finance_faye

recruiter said 3 days is the official policy for NJ roles and they don't negotiate on it individually. i didn't push on this one, that wasn't my reason for declining anyway.

corp_refugee

the 'competing offer' move working to get you from 135 to 142 is useful to know. some large pharma companies treat offers as final and don't move at all. sounds like Merck has some flexibility there if you come in with real leverage.